                         SEQUENCE LISTING

<110>  The University of Miami
 
<120>  DIAGNOSIS AND TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS WITH 
       PARP INHIBITORS

<130>  32286/51252A PC

<150>  US 62/413,812
<151>  2016-10-27

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  1630
<212>  DNA
<213>  Homo sapiens

<221>  misc_feature
<223>  Homo sapiens LIM domain only 2 (rhombotin-like 1), mRNA

<300>
<308>  BC035607.1
<309>  2003-10-07
<313>  (1)..(1630)

<400>  1
gaaggttaag tcctgagcag cagcagcagc tgcagccgcc tggagccagg ctgcgcgccc       60

cggcccccgc ctcggccgcg gcgcgcccgc agcccggtga ttcgctctct ctctttggcg      120

tttgaaggga gcgcggtgac tgtccttgag cgcggagggg cgagctcgcc ggcggagcgc      180

cggagcaagc ggaggcgcag gagcggcggc gacggcggcg gcggcggcgg cgcccgagca      240

cccgaggggg tccgagcccc ggcagccggc cagccccgcg ccacaaaggg agcgcccccg      300

ccgcccggca ccccgcctcc ctccccaatg tcctcggcca tcgaaaggaa gagcctggac      360

ccttcagagg aaccagtgga tgaggtgctg cagatccccc catccctgct gacatgcggc      420

ggctgccagc agaacattgg ggaccgctac ttcctgaagg ccatcgacca gtactggcac      480

gaggactgcc tgagctgcga cctctgtggc tgccggctgg gtgaggtggg gcggcgcctc      540

tactacaaac tgggccggaa gctctgccgg agagactatc tcaggctttt tgggcaagac      600

ggtctctgcg catcctgtga caagcggatt cgtgcctatg agatgacaat gcgggtgaaa      660

gacaaagtgt atcacctgga atgtttcaag tgcgccgcct gtcagaagca tttctgtgta      720

ggtgacagat acctcctcat caactctgac atagtgtgcg aacaggacat ctacgagtgg      780

actaagatca atgggatgat ataggcccga gtccccgggc atctttgggg aggtgttcac      840

tgaagacgcc gtctccatgg catcttcgtc ttcactctta ggcactttgg gggtttgagg      900

gtggggtaag ggatttctta ggggatggta gacctttatt gggtatcaag acatagcatc      960

caagtggcat aattcagggg ctgacacttc aaggtgacag aaggaccagc ccttgaggga     1020

gaacttatgg ccacagccca tccatagtaa ctgacatgat tagcagaaga aaggaacatt     1080

taggggcaag caggcgctgt gctatcatga tggaatttca tatctacaga tagagagttg     1140

ttgtgtacag acttgttgtg actttgacgc ttgcgaacta gagatgtgca attgatttct     1200

tttcttcctg gctttttaac tcccctgttt caatcactgt cctccacaca agggaaggac     1260

agaaaggaga gtggccattc tttttttctt ggcccccttc ccaaggcctt aagctttgga     1320

cccaaggaaa actgcatgga gacgcatttc ggttgagaat ggaaaccaca acttttaacc     1380

aaacaattat ttaaagcaat gctgatgaat cactgttttt agacaccttc attttgaggg     1440

gaggagttcc acagattgtt tctatacaaa tataaatctt aaaaagttgt tcaactattt     1500

tattatccta gattatatca aagtatttgt cgtgtgtaga aaaaaaaaac agctctgcag     1560

gcttaataaa aatgacagac tgaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa     1620

aaaaaaaaaa                                                            1630


<210>  2
<211>  158
<212>  PRT
<213>  Homo sapiens


<220>
<221>  MISC_FEATURE
<223>  LMO2

<300>
<308>  AAH35607
<309>  2003-10-07
<313>  (1)..(158)

<400>  2

Met Ser Ser Ala Ile Glu Arg Lys Ser Leu Asp Pro Ser Glu Glu Pro 
1               5                   10                  15      


Val Asp Glu Val Leu Gln Ile Pro Pro Ser Leu Leu Thr Cys Gly Gly 
            20                  25                  30          


Cys Gln Gln Asn Ile Gly Asp Arg Tyr Phe Leu Lys Ala Ile Asp Gln 
        35                  40                  45              


Tyr Trp His Glu Asp Cys Leu Ser Cys Asp Leu Cys Gly Cys Arg Leu 
    50                  55                  60                  


Gly Glu Val Gly Arg Arg Leu Tyr Tyr Lys Leu Gly Arg Lys Leu Cys 
65                  70                  75                  80  


Arg Arg Asp Tyr Leu Arg Leu Phe Gly Gln Asp Gly Leu Cys Ala Ser 
                85                  90                  95      


Cys Asp Lys Arg Ile Arg Ala Tyr Glu Met Thr Met Arg Val Lys Asp 
            100                 105                 110         


Lys Val Tyr His Leu Glu Cys Phe Lys Cys Ala Ala Cys Gln Lys His 
        115                 120                 125             


Phe Cys Val Gly Asp Arg Tyr Leu Leu Ile Asn Ser Asp Ile Val Cys 
    130                 135                 140                 


Glu Gln Asp Ile Tyr Glu Trp Thr Lys Ile Asn Gly Met Ile 
145                 150                 155             


